2019 - 2020

Categories:History
Author:
Origin:
Time of issue:2020-03-09
Views:0

(Summary description)
◆ Completing thebioequivalency evaluationof the first generic drug for rare diseases.
◆ Completing Phase I clinical trial of a new hypoglycemic drug.
◆ Raising 150 million yuaninSeries A+ round financing.

2019 - 2020

(Summary description)
◆ Completing thebioequivalency evaluationof the first generic drug for rare diseases.
◆ Completing Phase I clinical trial of a new hypoglycemic drug.
◆ Raising 150 million yuaninSeries A+ round financing.

Categories:History
Author:
Origin:
Time of issue:2020-03-09
Views:0

A heavy load and a long way to go

Previous: 2020 - 2021

Next: 2018 - 2019

Previous: 2020 - 2021

Next: 2018 - 2019

New Information | Series C financing of over 100 million yuan marks the first round of financing for Shengshi Taike, paving the way for commercialization of core innovative products

2024-09-04

Dr. Wang Tong, Chief Scientific Officer of Shengshi Taike, has been selected as a "Double Innovation Talent" in Jiangsu Province

Recently, the "Double Innovation Talent Plan" organized by the Jiangsu Provincial People's Government and the Provincial Talent Office was awarded a certificate of selection, and Dr. Wang Tong, Chief Scientific Officer of Shengshi Taike, was selected for the "2023 Jiangsu Province High level Innovation and Entrepreneurship Talent Introduction Plan". The Shengshi Taike R&D team led by Dr. Wang Tong is committed to the development of high-quality and differentiated small molecule innovative drugs, aiming to address major clinical pain points in the fields of blood sugar reduction, anti-tumor, and autoimmune diseases.

2024-07-31